Co-assembled Nanocomplexes of Peptide Neoantigen Adpgk and Toll-like Receptor 9 Agonist CpG ODN for Efficient Colorectal Cancer Immunotherapy.

[1]  S. Bhatia,et al.  Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics , 2020, Proceedings of the National Academy of Sciences.

[2]  Ying Hu,et al.  Multi-functional nanocomplex codelivery of Trp2 and R837 to activate melanoma-specific immunity. , 2020, International journal of pharmaceutics.

[3]  C. Drake,et al.  Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T cell immunity to tumor antigens , 2019, Nature Biotechnology.

[4]  Cheryl F. Lichti,et al.  MHC-II neoantigens shape tumor immunity and response to immunotherapy , 2019, Nature.

[5]  Z. Zeng,et al.  Neoantigen vaccine: an emerging tumor immunotherapy , 2019, Molecular Cancer.

[6]  Jong Oh Kim,et al.  Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy. , 2019, Acta biomaterialia.

[7]  E. Davila,et al.  An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell–Based Cancer Vaccine , 2019, Cancer Immunology Research.

[8]  Joseph A. Vetro,et al.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection. , 2019, International journal of pharmaceutics.

[9]  Jung Weon Lee,et al.  In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence. , 2019, ACS nano.

[10]  Zhiyong Qian,et al.  A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy. , 2019, ACS applied materials & interfaces.

[11]  Rachel S. Riley,et al.  Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.

[12]  J. Castle,et al.  Actively personalized vaccination trial for newly diagnosed glioblastoma , 2018, Nature.

[13]  Alyssa R. Richman,et al.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial , 2018, Nature.

[14]  Cunbao Liu,et al.  Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid‐modified cationic lipid‐PLGA hybrid nanoparticle vaccine in TC‐1‐grafted tumors , 2018, International journal of pharmaceutics.

[15]  John T. Wilson,et al.  Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. , 2018, Biomaterials.

[16]  S. Abrams,et al.  Peptide Delivery Systems for Cancer Vaccines , 2018, Advanced Therapeutics.

[17]  Xiaoqi Sun,et al.  Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. , 2018, ACS nano.

[18]  Aileen W. Li,et al.  A facile approach to enhance antigen response for personalized cancer vaccination , 2018, Nature Materials.

[19]  W. Gillanders,et al.  Preclinical and clinical development of neoantigen vaccines. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Abraham J. Koster,et al.  Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[21]  H. Shroff,et al.  Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy , 2017, Nature Communications.

[22]  Myunggi An,et al.  Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy. , 2017, Bioconjugate chemistry.

[23]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[24]  Jeffrey A. Engelman,et al.  Prospects for combining targeted and conventional cancer therapy with immunotherapy , 2017, Nature Reviews Cancer.

[25]  Xiaoyuan Chen,et al.  Efficient Nanovaccine Delivery in Cancer Immunotherapy. , 2017, ACS nano.

[26]  U. Gündüz,et al.  Changes in apoptosis-related gene expression and cytokine release in breast cancer cells treated with CpG-loaded magnetic PAMAM nanoparticles , 2016 .

[27]  J. Moon,et al.  Designer vaccine nanodiscs for personalized cancer immunotherapy , 2016, Nature materials.

[28]  C. Melief,et al.  Vaccines for established cancer: overcoming the challenges posed by immune evasion , 2016, Nature Reviews Cancer.

[29]  V. Buchholz,et al.  Role of memory T cell subsets for adoptive immunotherapy. , 2016, Seminars in immunology.

[30]  T. Chan,et al.  Cancer Neoantigens and Applications for Immunotherapy , 2015, Clinical Cancer Research.

[31]  Maxim N. Artyomov,et al.  Tumor neoantigens: building a framework for personalized cancer immunotherapy. , 2015, The Journal of clinical investigation.

[32]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[33]  Luis A. Brito,et al.  Vaccine adjuvant formulations: a pharmaceutical perspective. , 2013, Seminars in immunology.

[34]  K. Barrios,et al.  BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses , 2013, Cancer Immunology, Immunotherapy.

[35]  N. Hanagata.  Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system , 2012, International journal of nanomedicine.

[36]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[37]  Ying K. Tam,et al.  Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. , 2009, Advanced drug delivery reviews.

[38]  R. Coffman,et al.  Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.

[39]  A. Kelso,et al.  Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine design , 2005, Expert review of vaccines.

[40]  Gina R Petroni,et al.  MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma1 , 2005, The Journal of Immunology.

[41]  D. Klinman.  Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.

[42]  Shuguang Zhang.  Fabrication of novel biomaterials through molecular self-assembly , 2003, Nature Biotechnology.

[43]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[44]  L. Norton,et al.  Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  A. Krieg,et al.  CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.